Abstract
To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.
| Original language | English |
|---|---|
| Pages (from-to) | 592-596 |
| Number of pages | 5 |
| Journal | Journal of Thoracic and Cardiovascular Surgery |
| Volume | 90 |
| Issue number | 4 |
| State | Published - Dec 1 1985 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. A randomized trial. / Williams, Donald; Misbach, G. A.; Kruse, A. P.; Ivey, T. D.
In: Journal of Thoracic and Cardiovascular Surgery, Vol. 90, No. 4, 01.12.1985, p. 592-596.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. A randomized trial
AU - Williams, Donald
AU - Misbach, G. A.
AU - Kruse, A. P.
AU - Ivey, T. D.
PY - 1985/12/1
Y1 - 1985/12/1
N2 - To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.
AB - To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.
UR - http://www.scopus.com/inward/record.url?scp=0022387643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022387643&partnerID=8YFLogxK
M3 - Article
VL - 90
SP - 592
EP - 596
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
SN - 0022-5223
IS - 4
ER -